October 3, 2022British Journal of Pharmacology48 citationsOpen Access
Fifty years with aspirin and platelets
Key Result
Low-dose aspirin has been established over 50 years of clinical research as a life-saving antiplatelet drug and the cornerstone of antithrombotic therapy.
Structured PICO
I
Intervention
Low-dose aspirin
Provides a historical perspective on the 50-year development of low-dose aspirin as a cornerstone antiplatelet therapy.
Abstract
biosynthesis as a tool to investigate the clinical pharmacology of cyclooxygenase inhibition by aspirin in health and disease. What followed was a long, winding road of clinical research leading to the characterization of low-dose aspirin as a life-saving antiplatelet drug that still represents the cornerstone of antithrombotic therapy. Having witnessed and participated in these 50 years of aspirin research, I thought of providing a personal testimony of how things developed and eventually led to a remarkable success story of independent research.